Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03234556 · ClinicalTrials.gov registry record · NA

Diagnosing Clinically Significant Prostate Cancer In African American and White Men With Elevated PSA

A NA study of Health Status Unknown and Elevated PSA, sponsored by University of Southern California.

Active
Registry status
NA
Development phase
288
Enrollment target
4
Study locations

NCT03234556: Active NA study of Health Status Unknown and Elevated PSA, sponsored by University of Southern California.

NCT03234556 is a NA study of Health Status Unknown and Elevated PSA that is active but no longer recruiting, run by University of Southern California. The registered enrollment target is 288 participants, below the 1,280-participant average among 6 other Health Status Unknown trials with a reported enrollment target (77% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03234556, a NA study of Health Status Unknown and Elevated PSA, is active but no longer recruiting, sponsored by University of Southern California.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
288 participants
Enrollment target
4
Study locations

Study Summary

This randomized phase II trial studies how well systematic random biopsy or magnetic resonance imaging (MRI)-ultrasound image (US) fusion biopsy work in diagnosing prostate cancer in patients with elevated prostate specific antigen. Systematic random biopsy and MRI-US fusion biopsy may work better in improving the accuracy of prostate cancer detection.

Primary Outcome

Will code patients as having clinically significant prostate cancer if they are diagnosed with Gleason score \>= 7 or any Gleason score with core length \>= 5 mm or any Gleason score that includes Gleason pattern \>= 4 at initial systematic random biopsy.

Interventions

  • OTHER Laboratory Biomarker Analysis
  • PROCEDURE Biopsy of Prostate
  • DIAGNOSTIC_TEST Magnetic Resonance Imaging
  • DIAGNOSTIC_TEST MRI Ultrasound Fusion Guided Biopsy

Study Locations (4)

California

  • USC / Norris Comprehensive Cancer Center - Los Angeles

Maryland

  • University of Maryland - Baltimore

Michigan

  • Henry Ford Hospital Vattikuti Urology Institute - Detroit

New York

  • Memorial Sloan-Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 288 participants
Start Date 2017-09-25
Est. Completion 2028-05-23
Phase NA
University of Southern California

617 total trials

What the registry record for NCT03234556 still lists

NCT03234556 is an interventional study that assigns participants to a tested intervention. The registered 288 participants enrollment target is mid-sized for trials with a published cap, below the 1,280-participant average among 6 other Health Status Unknown trials with a reported enrollment target (77% lower).

The record links to 2 conditions, with Health Status Unknown appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT03234556 reports a single indexed study location in California, Maryland, Michigan.

Frequently Asked Questions

What is clinical trial NCT03234556 about?

NCT03234556 is a clinical study titled "Diagnosing Clinically Significant Prostate Cancer In African American and White Men With Elevated PSA". This randomized phase II trial studies how well systematic random biopsy or magnetic resonance imaging (MRI)-ultrasound image (US) fusion biopsy work in diagnosing prostate cancer in patients with elevated prostate specific antigen. Systematic random biopsy and MRI-US fusion biopsy may work better i...

What is the current status of trial NCT03234556?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 288 participants. The study started on 2017-09-25. Estimated completion is 2028-05-23.

What conditions does trial NCT03234556 study?

This clinical trial studies the following conditions: Health Status Unknown, Elevated PSA.

What interventions are being tested in trial NCT03234556?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Biopsy of Prostate (PROCEDURE), Magnetic Resonance Imaging (DIAGNOSTIC_TEST), MRI Ultrasound Fusion Guided Biopsy (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT03234556?

This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03234556 being conducted?

This trial has 4 study locations across California, Maryland, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Health Status Unknown

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02098265 · 288 participants · NA

    A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device

  • NCT03741777 · 288 participants · NA

    Comparison of Residual Gastric Volume Between Children Who Drink Different Clear Oral Fluid Volume

  • NCT03937635 · 288 participants · Phase 3

    Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

  • NCT04621877 · 288 participants · NA

    Lay-Delivered Behavioral Activation in Senior Centers

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03234556, the US trial registry maintained by the National Library of Medicine. NCT03234556 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.